Form 4: Axsome Director Roger Jeffs Acquires Shares via RSU Vesting

Axsome Therapeutics Director Roger Jeffs has increased his direct ownership to 58,939 shares following the scheduled vesting of restricted stock units.

Summary

• Director Roger Jeffs converted 1,429 restricted stock units (RSUs) into common stock on June 8, 2026.
• The RSUs were originally granted on June 6, 2025, and vested in full on the one-year anniversary.
• The conversion was executed on a one-for-one basis at no cost to the reporting person.
• Following the transaction, Roger Jeffs directly owns 58,939 shares of Axsome Therapeutics common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive routine event; while not an open-market buy, the director's retention of the vested shares is a stable signal.

Positives

• Insider maintains a significant equity position in the company.
• The director did not sell any shares immediately following the vesting event, suggesting continued confidence.
• The transaction follows a transparent, pre-determined vesting schedule.

Negatives

• The transaction is a routine compensation event and does not represent an open-market purchase.

Risks

• No specific risks were disclosed in this Form 4 filing.

Future Outlook

The filing does not provide specific forward-looking guidance, but the retention of shares by a director typically aligns with a positive long-term outlook for the company's performance.

Management Comments

• Restricted stock units convert into common stock on a one-for-one basis.

Industry Context

StockSavvy.ai notes that in the biotechnology sector, director equity participation is a standard mechanism to align board interests with long-term shareholder value, particularly during critical clinical or commercial phases.

Comparison to Industry Standards

• The one-year cliff vesting for director RSUs is a standard practice among NASDAQ-listed biotech companies like Sage Therapeutics and Intra-Cellular Therapies.
• The size of the grant (1,429 units) is consistent with mid-cap biotech board compensation structures.

Related Party Transactions

• The issuance of 1,429 shares to Director Roger Jeffs was conducted as part of the company's established equity incentive compensation plan.

Stakeholder Impact

• Shareholders may view the director's increased share count as a sign of ongoing commitment to the company's strategic direction.

Next Steps

• Monitor for any subsequent Form 4 filings that might indicate the sale of these shares for tax obligations or diversification.

Key Dates

Recommendation

This filing represents a routine administrative conversion of previously granted equity and does not provide new material information that would alter a fundamental valuation of the company.

Keywords

Axsome Therapeutics, AXSM, Insider Trading, Roger Jeffs, Restricted Stock Units, Biotechnology, SEC Form 4, Executive Compensation